Sanofi launches Avaxim Junior in the UK for Active Immunisation Against Infection Caused by the Hepatitis A Virus in 1 – 15 y.o.
Sanofi announced Tuesday the launch of AVAXIM® Junior in the UK, an inactive hepatitis A vaccine indicated for use in children aged 12 months to 15 years inclusive to prevent infection caused by the hepatitis A virus.